KMPH - KemPharm, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.8700
-0.0150 (-1.69%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.8850
Open0.8865
Bid0.0000 x 2900
Ask0.0000 x 1000
Day's Range0.8602 - 0.9000
52 Week Range0.7100 - 5.0500
Volume140,902
Avg. Volume216,839
Market Cap26.151M
Beta (3Y Monthly)3.03
PE Ratio (TTM)N/A
EPS (TTM)-1.7290
Earnings DateAug 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.41
Trade prices are not sourced from all markets
  • Local pharmaceutical firm enters partnership valued up to $493M
    American City Business Journals

    Local pharmaceutical firm enters partnership valued up to $493M

    A Celebration-based pharmaceutical company could end up with an extremely large investment if its product candidates for ADHD treatment are approved. KemPharm Inc. (Nasdaq: KMPH) entered a licensing agreement with Cambridge, Massachusetts-based Gurnet Point Capital LLC on up to $493 million in upfront, sales and development milestone payments. The company will receive $10 million upfront, and could receive pre-approval cost reimbursements, regulatory milestone payments as well as sales milestone payments valued up to $483 million and separate sales royalties as part of the deal.

  • GlobeNewswire

    KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital

    KemPharm also announced its entry into a debt exchange agreement and other amendments to its senior debt facility (the Exchange Agreement) with funds managed by Deerfield Management Company, L.P. (Deerfield), potentially reducing its debt outstanding by up to $22 million over a period of 240 days, and up to $30 million, in the aggregate. Under the terms of the License Agreement, KemPharm will receive an upfront payment of $10 million, and is eligible to receive pre-approval cost reimbursements, regulatory milestone payments both prior to and upon approval, and sales milestone payments totaling as much as $483 million, as well as tiered royalty payments on a product-by-product basis for net sales under the License Agreement.  These royalty rates range, on a product-by-product basis, from a percentage in the high single digits up to the mid-twenties for U.S. net sales, and a percentage in the low to mid-single digits of net sales in each country outside of the U.S.

  • GlobeNewswire

    KemPharm Reports Second Quarter 2019 Results

    CELEBRATION, Fla., Aug. 13, 2019 -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today.

  • Implied Volatility Surging for KemPharm (KMPH) Stock Options
    Zacks

    Implied Volatility Surging for KemPharm (KMPH) Stock Options

    Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

  • GlobeNewswire

    KemPharm Reports First Quarter 2019 Results

    Development & Regulatory Highlights: Completed KP415 Pre-NDA Meeting with FDAProvided Update on APADAZ® Formulary AdoptionAnnounced FDA Approval of sNDA for Two Additional.

  • GlobeNewswire

    KemPharm Completes KP415 Pre-NDA Meeting with FDA

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company concluded a pre-New Drug Application ("NDA") meeting with the U.S. Food and Drug Administration ("FDA") for KP415, KemPharm’s investigational attention-deficit/hyperactivity disorder (ADHD) product candidate that contains serdexmethylphenidate (a prodrug of d-methylphenidate) and d-methylphenidate.

  • Thomson Reuters StreetEvents

    Edited Transcript of KMPH earnings conference call or presentation 28-Feb-19 9:30pm GMT

    Q4 2018 KemPharm Inc Earnings Call

  • GlobeNewswire

    KemPharm Provides Update on APADAZ® Formulary Adoption

    Conference Call Scheduled for Today, Wednesday, March 13, 2019 at 8:30 a.m. ET Highlights: According to MMIT estimates, the authorized generic for APADAZ has unrestricted.

  • Loss-Making KemPharm, Inc. (NASDAQ:KMPH) Expected To Breakeven
    Simply Wall St.

    Loss-Making KemPharm, Inc. (NASDAQ:KMPH) Expected To Breakeven

    KemPharm, Inc.'s (NASDAQ:KMPH): KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company’s loss has recently broadened since it announced a -US$43.4mRead More...

  • GlobeNewswire

    KemPharm to Present at Upcoming Investor Conferences

    CELEBRATION, Fla., March 05, 2019 -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today.

  • GlobeNewswire

    KemPharm Reports Q4 and FY 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Completed KP415.

  • ACCESSWIRE

    KemPharm, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 28, 2019 / KemPharm, Inc. (NASDAQ: KMPH ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 at 4:30 PM ...

  • GlobeNewswire

    KemPharm to Report Fourth Quarter and Year End 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, February 28, 2019, 4:30 p.m. ET CELEBRATION, Fla., Feb. 21, 2019 -- KemPharm, Inc..

  • GlobeNewswire

    KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced continued enhancements to its U.S. and global intellectual property estate governing its portfolio of prodrug product candidates.  The United States Patent and Trademark Office (USPTO) issued seven (7) new patents to KemPharm during 2018 related to several of its compound families, including KP201, KP303, KP511, KP606 and KP746. In addition, KemPharm has augmented and strengthened the global patent estate for KP415 with the addition of issued patents last year in Canada, Japan and Korea.

  • What You Must Know About KemPharm, Inc.’s (NASDAQ:KMPH) Beta Value
    Simply Wall St.

    What You Must Know About KemPharm, Inc.’s (NASDAQ:KMPH) Beta Value

    Anyone researching KemPharm, Inc. (NASDAQ:KMPH) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors Read More...

  • GlobeNewswire

    KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting

    Posters include intranasal and oral HAP data for serdexmethylphenidate (SDX), as well as PK data for KP415 Intranasal HAP data selected to be presented during oral “data.

  • GlobeNewswire

    KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for two additional strengths of APADAZ®, an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP). The approval of these new dosage strengths, 4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP, follows the New Drug Application (NDA) approval on February 23, 2018 of the 6.12 mg benzhydrocodone/325 mg APAP dosage strength of APADAZ.

  • GlobeNewswire

    New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Jan. 02, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided a corporate update on the ongoing partnering process for its co-lead clinical development product candidates intended for the treatment of attention-deficit/hyperactivity disorder (ADHD), KP415 and KP484. “As we first announced in August, we have been working through a formal partnering process for our ADHD assets, KP415 and KP484, and to date, we have generated a significant amount of interest,” said Travis Mickle, Ph.D., President and Chief Executive Officer of KemPharm. Dr. Mickle continued, “The interest in our ADHD product candidates was not a surprise to us based on our understanding of market dynamics and the ability of our prodrug approach to potentially meet key unmet needs voiced by prescribers and patients. We remain emboldened by market research and the insights of ADHD opinion leaders that the potential for KP415 and KP484 to provide early onset of action, longer duration of therapy and lower abuse potential, has the potential to position both product candidates as differentiated methylphenidate products within the high-demand ADHD treatment landscape.

  • GlobeNewswire

    KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research assessing the intravenous (IV) abuse potential of serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), will be presented by Megan Shram, Ph.D., at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP). SDX is the major active pharmaceutical ingredient in KP415 and KP484, KemPharm’s co-lead clinical development product candidates intended for the treatment of attention-deficit/hyperactivity disorder (ADHD), as well as KP879, a newly developed product candidate designed for the treatment of Stimulant Use Disorder (SUD).

  • PR Newswire

    KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing

    CELEBRATION, Fla., Dec. 11, 2018 /PRNewswire/ -- KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., presented at an interactive online investor conference. KemPharm's presentation will be available for 90 days.  In addition, investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.

  • PR Newswire

    Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th

    Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Dec. 4, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

  • PR Newswire

    KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th

    CELEBRATION, Fla., Dec. 3, 2018 /PRNewswire/ -- KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., will present live at VirtualInvestorConferences.com on December 6, 2018.

  • What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)?
    Simply Wall St.

    What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)?

    A look at the shareholders of KemPharm Inc (NASDAQ:KMPH) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies Read More...

  • GlobeNewswire

    Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.